Conference Track

Advances in HBV Treatment: 2009

Source: CCO Independent Conference Coverage of the 2009 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

No Increased Risk of Birth Defects Associated With Prenatal Lamivudine or Tenofovir Exposure In Antiretroviral Pregnancy Registry Study
HBsAg Levels Reduced by Telbivudine Treatment in HBeAg-Positive Patients With Chronic Hepatitis B From GLOBE Study
Long-term Sustained Response and HBsAg Loss After Discontinuation of 4-5 Years of Adefovir Therapy in HBeAg-Negative Patients
Entecavir Efficacy Not Affected by Previous Adefovir Treatment or Resistance in Chronic HBV–Infected Patients
Entecavir Resistance Rare in Nucleoside-Naive HBV Patients Through 6 Years
Tenofovir Highly Effective for the Treatment of Chronic HBV Infection in Both Cirrhotic and Noncirrhotic Patients
Equivalent Efficacy of Tenofovir/Emtricitabine vs Tenofovir Monotherapy Through Week 96 in Patients With HBV and Persistent Viremia on Adefovir
High Risk of Peripheral Neuropathy Associated With Telbivudine Plus Peginterferon alfa-2a vs Telbivudine Monotherapy
Viral Suppression Maintained in Subset of HBeAg-Positive and HBeAg-Negative Patients Without Evidence of Genotypic Resistance After 2 Years of Telbivudine Who Continued Treatment Through 3 Years
Superior HBV Seroprotection With 2-Dose Combination HBsAg-1018 Immunostimulatory Sequence Vaccine vs Currently Approved HBV Vaccine

Expert Analysis

Advances in HBV Treatment: 2009

Faculty:

Maria Buti, MD
Anna S. F. Lok, MD
Patrick Marcellin, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite new data on efficacy and resistance during long-term nucleos(t)ide analogue therapy for the treatment of chronic HBV infection
Describe the latest findings on adverse events associated with the use of nucleos(t)ide analogues and their safety in the settings of pregnancy and liver cirrhosis
Discuss the relationship between on-treatment HBsAg decline and serologic response during telbivudine therapy
Summarize recent data on the sustained efficacy of long-term adefovir therapy during prolonged posttreatment follow-up

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: June 17, 2009

Expiration Date: June 16, 2010

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.